EUVIMEDEUVIMED entdecken
Crossref

Long‐term combination therapy with metformin and oxymetholone in a Fanconi anemia mouse model

Craig Dorrell, Alexander M Peters, Qingshuo Zhang, Niveditha Balaji, Kevin Baradar, Makiko Mochizuki-Kashio, Angela Major, Milton Finegold, Chih-Wei Liu, Kun Lu, Markus Grompe iD

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.31030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Craig Dorrell und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Papé Family Pediatric Research Institute, Stem Cell Center, Pediatric Blood & Cancer Biology Program, Oregon Health & Scien…. Hauptthemen laut MEDLINE: Metformin, Fanconi Anemia, Oxymetholone, Disease Models, Animal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: NHLBI NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fanconi anemia (FA) is a disease caused by defective deoxyribonucleic acid (DNA) repair that manifests as bone marrow failure, cancer predisposition, and developmental defects. We previously reported that monotherapy with either metformin (MET) or oxymetholone (OXM) improved peripheral blood (PB) counts and the number and functionality of bone marrow hematopoietic stem progenitor cells (HSPCs) number in Fancd2 −/− mice. To evaluate whether the combination treatment of these drugs has a synergistic effect to prevent bone marrow failure in FA, we treated cohorts of Fancd2 −/− mice and wildtype controls with either MET alone, OXM alone, MET+OXM, or placebo diet from age 3 weeks to 18 months. The OXM treated animals showed modest improvements in blood parameters including platelet count ( p = .01) and hemoglobin levels ( p < .05). In addition, the percentage of quiescent hematopoietic stem cell (HSC) (LSK [Lin − Sca + c‐Kit + ]) was significantly increased ( p = .001) by long‐term treatment with MET alone. The combination of metformin and oxymetholone did not result in a significant synergistic effect in any hematopoietic parameter. Gene expression analysis of liver tissue from these animals showed that some of the expression changes caused by Fancd2 deletion were partially normalized by metformin treatment. Importantly, no adverse effects of the individual or combination therapies were observed, despite the long‐term administration. We conclude that androgen therapy is not a contraindication to concurrent metformin administration in clinical trials. Highlights Long‐term coadministration of metformin in combination with oxymetholone is well tolerated by Fancd2 −/− mice. Hematopoietic stem cell quiescence in mutant mice was enhanced by treatment with metformin alone. Metformin treatment caused a partial normalization of gene expression in the livers of mutant mice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminFanconi AnemiaOxymetholoneDisease Models, AnimalDrug Therapy, CombinationAnimalsMiceFanconi Anemia Complementation Group D2 ProteinMice, KnockoutHematopoietic Stem Cells

Stichwörter der Autor:innen

Fanconi anemiaandrogen therapychemopreventionmetformin

Substanzen

MetforminOxymetholoneFanconi Anemia Complementation Group D2 ProteinFancd2 protein, mouse

Autor:innen und Institutionen

  • Department of Pediatrics, Papé Family Pediatric Research Institute, Stem Cell Center, Pediatric Blood & Cancer Biology Program, Oregon Health & Science University, Portland, Oregon, USA.
  • Department of Pathology, Texas Children's Hospital, Houston, Texas, USA.
  • Department of Environmental Sciences and Engineering, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

ORCID-Profile: Markus Grompe

Förderung

  • NHLBI NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Dorrell, C., Peters, A. M., Zhang, Q., Balaji, N., Baradar, K., Mochizuki-Kashio, M., Major, A., Finegold, M., Liu, C. W., Lu, K., & Grompe, M. (2024). Long‐term combination therapy with metformin and oxymetholone in a Fanconi anemia mouse model. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31030

Vancouver

Dorrell C, Peters AM, Zhang Q, Balaji N, Baradar K, Mochizuki-Kashio M, et al. Long‐term combination therapy with metformin and oxymetholone in a Fanconi anemia mouse model. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31030

BibTeX
@article{Dorrell2024,
  author = {Dorrell, Craig and Peters, Alexander M and Zhang, Qingshuo and Balaji, Niveditha and Baradar, Kevin and Mochizuki-Kashio, Makiko and Major, Angela and Finegold, Milton and Liu, Chih-Wei and Lu, Kun and Grompe, Markus},
  title = {Long‐term combination therapy with metformin and oxymetholone in a Fanconi anemia mouse model},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.31030}
}
Kostenlos starten →